
	Where results make sense

Topic: Cubist

Related Topics

Jean Metzinger

Pablo Picasso

Jacques Villon

Modernist poetry in English

Georges Braque

Surrealist

Jacques Lipchitz

Still life

Juan Gris

Marcel Duchamp

Fernand Leger

Venice Biennale

Robert Delaunay

Existentialism

Collage

In the News (Fri 1 Jun 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	cubism - Encyclopedia.com
		Among the specific elements abandoned by the cubists were the sensual appeal of paint texture and color, subject matter with emotional charge or mood, the play of light on form, movement, atmosphere, and the illusionism that proceeded from scientifically based perspective.
		The cubist break with the tradition of imitation of nature was completed in the works of Picasso, Braque, and their many groups of followers.
		Although the cubist groups were largely dispersed after World War I, their collective break from visual realism had an enriching and decisive influence on the development of 20th-century art.
	www.encyclopedia.com /doc/1E1-cubism.html (861 words)

	Cubism - Wikipedia, the free encyclopedia
		In cubist artworks objects are broken up,analyzed, and reassembled in an abstracted form — instead of rendering objects from a single fixed angle, the artist depicts the subject from multiple angles simultaneously as an attempt to present the subject in the most complete manner.
		Picasso and Braque worked alongside one another (1906-1909 pre-cubism) and then started to work hand-in-hand to further advance their concepts into what was later termed "analytical cubism" (autumn 1909 to winter 1911/1912), a style in which densely patterned near-monochrome surfaces of incomplete directional lines and modelled forms constantly play against one another.
		Picasso's painting of the Les Demoiselles d'Avignon is not considered cubist, however it is considered essential in the development of the movement.
	en.wikipedia.org /wiki/Cubism (1038 words)

	Sample Contracts - Manufacturing and Supply Agreement - ACS Dobfar SpA and Cubist Pharmaceuticals Inc. - Competitive ... (Site not responding. Last check: 2007-10-21)
		Cubist has commenced Phase III clinical trials of daptomycin and intends to obtain approval to market and sell the drug for the treatment of serious and life threatening infections in humans.
		Cubist Technology specifically includes, but is not limited to, all process development technology developed for Cubist as part of the Materials Transfer and Confidentiality Agreement between Cubist and ACSD dated February 11, 1998.
		Cubist is not granted, and shall not exercise, the right or authority to assume or create any obligation or responsibility on behalf of or in the name of ACSD or its Affiliates.
	contracts.onecle.com /cubist/acs-dobfar.mfg.2001.09.30.shtml (7441 words)

	Cubist Pharmaceuticals Says Drug Flunked Geography Test
		Cubist is testing Cidecin as a treatment for serious pneumonia, but in a late-stage test that compared it with an existing treatment, the drug failed to show superior efficacy, the company said.
		Cubist said it is suspending patient enrollment in a second, late-stage Cidecin pneumonia trial until it can further review the results from the first test.
		Cubist's original plan was to seek Cidecin approval from the Food and Drug Administration for both diseases in the third quarter.
	www.thestreet.com /tech/adamfeuerstein/10006893.html (278 words)

	Cubist Presents at Bio '98 Investor & Partnering Conference
		Cubist is developing daptomycin to treat hospitalized patients with complicated skin and soft tissue infections, bacteremia and urinary tract infections caused by drug resistant bacteria, including MRSA and VRE.
		Cubist plans to initiate Phase III clinical trials of intravenous daptomycin for the treatment of complicated skin and soft tissue infections in late 1998 or early 1999.
		Cubist Safeharbor Statement Statements contained herein that are not historical facts, including the Company's expectation that it will initiate Phase III clinical trials in late 1998 or early 1999, may be forward-looking statements that are subject to a variety of risks and uncertainties.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-16-1998/0000683579&EDATE= (459 words)

	Cubist - Uncyclopedia, the content-free encyclopedia
		Cubist is a language created by the artist and ranconteur Picasso in 1930, following a plea on behalf of the wretched Cubans by Robert Downey Jr.
		Picasso developed the precursor of Cubist, Boxist, during a three-day picnic in the woods with Winston Churchill, Oprah and some soft toys.
		The underlying principle of Cubist is that all words must simultaneously describe all concepts relating to the phrase at the moment the phrase is spoken.
	uncyclopedia.org /wiki/Cubist (356 words)

	SD Talk Science & Society: Nanosphere, Inc.; Cubist Pharmaceuticals; Applied Nanotech, Inc.
		Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of drugs that meet significant unmet medical needs.
		In the U.S., Cubist markets Cubicin (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides, for the indication of complicated skin and skin structure infections caused by Gram-positive bacteria.
		Cubist's preclinical pipeline includes an oral version of ceftriaxone, a broad-spectrum cephalosporin antibiotic, and other novel members of the lipopeptide class.
	www.sdtalk.com /archive.asp?aid=1463 (631 words)

	Cubist Pharmaceuticals, Inc. (Site not responding. Last check: 2007-10-21)
		Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections.
		Cubist recently announced the successful completion of the first of two pivotal Phase III trials examining the safety and efficacy of Cidecin in the treatment of complicated skin and soft tissue infections caused by Gram-positive bacteria.
		Cubist is also developing an oral formulation of daptomycin and an oral version of ceftriaxone, the first orally active version of the largest-selling intravenous antibiotic worldwide, Rocephin®.
	www.acor.org /drugs/pipeline/companies/1354.profile (301 words)

	Cubist Pharmaceuticals, Inc. - Company Profile - Computer Business Review
		Cubist is a specialty pharmaceutical company focused on the research and development of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections.
		Cubist is also applying its technologies to identify additional novel compounds with a broad spectrum of activity against a variety of infections.
		Furthermore, Cubist is currently evaluating the safety and efficacy of CUBICIN for the treatment of infective endocarditis and bacteremia caused by Staphylococcus aureus in an international Phase 3 clinical trial.
	www.cbronline.com /companyprofile.asp?guid=F966733A-72EC-4D97-AF10-389E58723ED6 (1312 words)

	FDA Warning Letter, Cubist Pharmaceuticals (Daptomycin)
		Cubist representatives promoted its daptomycin product in the commercial exhibit hall at the IDSA meeting prior to FDA approval by disseminating a booklet that contained 14 abstracts of clinical studies, a published review article entitled.
		Cubist presents misleading information on their website that fail to disclose facts that are material in light of’ the representations made about daptomycin.
		Cubist fails to present that there have been cases of reversible muscle toxicity at lower doses and irreversible muscle toxicity at higher doses of daptomycin.
	www.pharmcast.com /WarningLetters/November2000/Cubist1100.htm (584 words)

	Cubist Pharmaceuticals, Inc. (Site not responding. Last check: 2007-10-21)
		Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) is focused on becoming a global leader in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections.
		Cubist is evaluating the safety and efficacy of Cidecin® (daptomycin for injection) in the EDGE (Evaluation of Daptomycin against Gram-positive Entities) clinical trial program and has broadened its pipeline to include multiple pre-clinical drug candidates.
		Cubist is headquartered in Lexington, MA and has operations in Vancouver, BC, Canada and Slough, UK.
	www.stat.ufl.edu /vlib/jobs/cubist.html (274 words)

	In the Skin of a Lion as a Cubist Novel (Site not responding. Last check: 2007-10-21)
		Although Cubist writing is notoriously difficult to define, In the Skin of a Lion does display what Wendy Steiner sees as the two central aspects of the Cubist analogy in her book The Colors of Rhetoric (1982): stylistic parallelism and a comparison of ideologies.
		In a Cubist painting, according to Berger, 'the complexity of the forms and the ''discontinuity'' of space remind [the spectator] that his view from that place is bound to be only partial' ('The Moment of Cubism,' 25).
		One might argue that Cubist techniques are notoriously difficult to sustain in prose, on account of their heightened spatial emphasis, and that even those novels that are widely viewed as experimental and as belonging to the literary Cubist genre, such as Gertrude Stein's The Autobiography of Alice B. Toklas (1933), contain much conventionally linear writing.
	www.utpjournals.com /product/utq/673/673_simmons.html (6625 words)

	An Overview of Cubist
		Cubist does this by building a model containing one or more rules, where each rule is a conjunction of conditions associated with a linear expression.
		To continue the illustration: when Cubist is allowed to choose a model on the basis of the 596 training cases and the number of nearest neighbors is not specified, it opts for a composite model using a single nearest neighbor.
		Cubist incorporates a facility to extract a random sample from a dataset, construct a model from the sample, and then test the model on a disjoint collection of cases.
	www.rulequest.com /cubist-win.html (5771 words)

	Cubist Pharmaceuticals, Inc. (Site not responding. Last check: 2007-10-21)
		Cubist is focusing on drugs for gram positive and gram negative bacteria which have developed resistance to current antibiotic therapies.
		Cubist is involved in the development of small molecule compounds aimed at inhibiting protein synthesis in bacterial and fungal pathogens.
		Cubist's mission is to establish itself as an infectious disease chemotherapy company that can respond to the challenges posed by the emergence in pathogenic organisms that have developed resistance to current therapeutic agents.
	www.informagen.com /Resource_Informagen/report.php?mrn=1101 (126 words)

	Cubist shares soar - Mar. 7, 2002
		Cubist said it has received correspondence from the U.S. Food and Drug Administration indicating that the NDA for Cidecin would be reviewed and accepted.
		Cubist is first seeking approval for the drug to treat skin and soft tissue infections, but the company is also conducting Phase III clinical trials for the drug's treatment of community-acquired pneumonia and other infections.
		Cubist is also negotiating for a partner to market the drug in Japan.
	money.cnn.com /2002/03/07/companies/cubist (253 words)

	Cubist Presents at Chase H&Q Healthcare Conference
		Cubist is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel antinfectives to treat infections caused by bacterial and fungal pathogens.
		Cubist is applying its VITA(TM) (Validation In vivo of Target for Antiinfectives) technology to validate unique targets and to build assays to identify additional novel compounds with a broad spectrum of activity against serious infectious organisms such as methicillin resistant Staphyloccocus aureus (MRSA) and vancomycin resistant enterococci (VRE).
		Cubist's ChemInformatics technology uniquely captures information contained in high- throughput screening data sets to generate new pharmacophores with enhanced biological activity.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-12-2000/0001113936&EDATE= (432 words)

	No Dicey Results for Cubist [Fool.com] January 29, 2007
		Cubist received approval from the FDA for a market-expanding new use for its antibiotic treatment Cubicin and grew revenues 61% vs. 2005.
		Cubist had already pre-released its sales numbers for the fourth quarter three weeks ago, so its sales numbers came as no surprise.
		Several other stories in the media mentioned Cubist's "lackluster" outlook for the first quarter this year, where sales are expected to be flat versus the fourth quarter.
	www.fool.com /investing/small-cap/2007/01/29/no-dicey-results-for-cubist.aspx (480 words)

	Cubist highlights FDA's antibiotic resistance - Nature Biotechnology (Site not responding. Last check: 2007-10-21)
		In the first of the CAP studies, Cidecin was effective in 79% of patients compared with 87% of patients treated with Rocephin, thereby failing the non-inferior "test" by a narrow margin.
		To date, the FDA found acceptable trial data showing that there was a 95% probability that the cure rate of the test antibiotic was not more than 10−20% (the "delta value") lower than that of the comparator.
		Cubist took on this challenge, but failed to reach this goal in the CAP trial.
	www.nature.com /cgi-taf/DynaPage.taf?file=/nbt/journal/v20/n3/full/nbt0302-206.html (808 words)

	Healthcare Sales & Marketing Network News: Cubist Pharmaceuticals Provides Update on CUBICIN Launch
		Cubist plans to conduct additional studies on CUBICIN during 2004 in renally impaired patients and in patients suffering from febrile neutropenia, osteomyelitis, surgical wound infections and other indications.
		Cubist recently launched CORE(SM) (CUBICIN Outcomes Registry and Experience), a multicenter retrospective registry program designed to collect information on patients who have received CUBICIN therapy; data from the registry will be made available to participants and published periodically.
		Cubist is focused on three key issues in 2004 and beyond: successfully commercializing CUBICIN in the U.S. and supporting its partners worldwide, expanding and progressing the company's pipeline and improving the company's capital structure.
	salesandmarketingnetwork.com /news_release.php?ID=14906 (1114 words)

	Gilead -- Cubist Pharmaceuticals and Gilead Sciences Announce European Commercialization Agreement for Investigational ...
		Cubist has multiple ongoing Phase III clinical trials of Cidecin, the IV formulation, to evaluate the efficacy and safety in the treatment of complicated skin and soft tissue infection (cSST), community-acquired pneumonia (CAP) and complicated urinary tract infection (cUTI).
		Cubist Pharmaceuticals is focused on becoming a global leader in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections.
		Cubist is evaluating the safety and efficacy of Cidecin (daptomycin for injection) in the EDGE (Evaluation of Daptomycin against Gram-positive Entities) clinical trial program and is engaged in multiple, strategic partnerships, including Novartis Pharma AG, Merck & Co and Schering-Plough for the discovery and development of novel antiinfectives.
	www.gilead.com /wt/sec/pr_978972834 (790 words)

	Executive Briefing: Cubist: The Virtues of Pipeline Diversification
		Rejiggering the dosing schedule, Cubist not only proved the drug safe, but moved it rapidly through clinicals, just in time to benefit from the biotech bull market of 2000 by raising a total of $142 million to help fund daptomycin’s development and launch.
		Cubist used part of the money it raised in 2000 and 2001 to rapidly expand its one-drug pipeline.
		Cubist is also working on an oral version of Roche’s intravenous antbiotic, ceftriaxone (Rochephin), a $1 billion-plus product last year.
	www.windhover.com /contents/monthly/exex/e_2002800073.htm (700 words)

	MBC: Member Companies (Site not responding. Last check: 2007-10-21)
		Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that meet unmet medical needs in the acute care environment.
		Cubist expects to file a supplemental New Drug Application (sNDA) before year-end 2005 seeking priority review for approval to add S. aureus endocarditis and bacteremia to the indication statement for CUBICIN.
		Cubist's pipeline includes HepeX-B(tm), a monoclonal antibody biologic currently in the second of two Phase 2 trials to determine its potential for the prevention of infection by the Hepatitis B virus (HBV) in liver transplant patients, and research efforts focused on novel members of the lipopeptide class of molecules and on natural products discovery.
	www.massbio.org /members/detail.php3?MEMBER_ID=53 (204 words)

	News: Cubist Pharmaceuticals Announces Fourth Quarter 2006 U.S. Net Product Revenues of $56.2 Million and Full Year ...
		Cubist will issue its full earnings release and host its fourth quarter and full year 2006 earnings conference call and webcast with slides on Wednesday, January 24th.
		Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
		Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such statements are subject to a variety of risks and uncertainties.
	www.genengnews.com /news/bnitem.aspx?name=11077432 (533 words)

	Boston.com / Your Life / Health & Fitness / Diseases & Treatments / Cubist pulls Web page after warning by FDA
		Cubist Pharmaceuticals Inc. of Lexington said yesterday it took down a Web page promoting its flagship antibacterial drug after federal regulators told the company the site contained misleading information.
		Cubist's Cubicin is an injectable version of a drug meant to treat complex skin infections, based on the drug daptomycin that Cubist licensed from
		But according to the FDA, one example of faulty promotion on Cubist's website came when the company claimed Cubicin was proven clinically successful against two types of staphylococcus, a bacteria found on the skin than can cause infections in wounds.
	www.boston.com /yourlife/health/diseases/articles/2004/08/25/cubist_pulls_web_page_after_warning_by_fda (422 words)

	Guillaume Apollinaire, The Cubist Painters; Apollinaire and Cubism Romanic Review - Find Articles
		Guillaume Apollinaire, The Cubist Painters; Apollinaire and Cubism
		The poet's text, faithfully reproduced down to an approximation of the original design and layout and, for the first time, with the same plates reproducing the discussed artists' works as had been included by Apollinaire, is itself divided into two parts: first a theoretic text, titled Aesthetic Meditations, on the beauties of "modern," i.e.
		Cubist, painting, and then The Cubist Painters proper, a series of essays on nine French Cubist painters of the day, giving pride of place to Picasso and Braque before continuing to Metzinger, Gleizes, Laurencin, Gris, Léger, Picabia and Duchamp, as well as one sculptor, Duchamp-Villon.
	www.findarticles.com /p/articles/mi_qa3806/is_200411/ai_n9478360 (352 words)

	ABC Antiques Glassware,Depression,Patterns,Cubist Directory (Site not responding. Last check: 2007-10-21)
		This is the 2 5/8" creamer in the Cube or "Cubist" pattern made by the Jeannette Glass Company from 1929 to 1933.
		This is the larger size, 3" sugar with lid in the Cube or "Cubist" pattern made by the Jeannette Glass Company from 1929 to 1933.
		This is the 6" sherbet plate in the Cube or "Cubist" pattern made by the Jeannette Glass Company from 1929 to 1933.
	www.trocadero.com /abcantiques/catalog/Glassware:Depression:Patterns:Cubist.html (306 words)

Try your search on: Qwika (all wikis)